Yield10 Bioscience Stock Probability Of Bankruptcy
| YTENDelisted Stock | USD 1.90 0.04 2.06% |
Yield10 |
Yield10 Bioscience Company odds of distress Analysis
Yield10 Bioscience's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Yield10 Bioscience Probability Of Bankruptcy | Over 100% |
Most of Yield10 Bioscience's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Yield10 Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Yield10 Bioscience probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Yield10 Bioscience odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Yield10 Bioscience financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Yield10 Bioscience has a Probability Of Bankruptcy of 100%. This is 125.53% higher than that of the Biotechnology sector and 139.52% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Yield10 Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Yield10 Bioscience's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Yield10 Bioscience could also be used in its relative valuation, which is a method of valuing Yield10 Bioscience by comparing valuation metrics of similar companies.Yield10 Bioscience is currently under evaluation in probability of bankruptcy category among its peers.
Yield10 Fundamentals
| Return On Equity | -15.08 | ||||
| Return On Asset | -1.5 | ||||
| Operating Margin | (240.28) % | ||||
| Current Valuation | 3.96 M | ||||
| Shares Outstanding | 642.54 K | ||||
| Shares Owned By Insiders | 12.59 % | ||||
| Shares Owned By Institutions | 11.79 % | ||||
| Number Of Shares Shorted | 60.7 K | ||||
| Price To Earning | (3.19) X | ||||
| Price To Book | 11.23 X | ||||
| Price To Sales | 79.63 X | ||||
| Revenue | 60 K | ||||
| Gross Profit | (7.3 M) | ||||
| EBITDA | (14.13 M) | ||||
| Net Income | (14.46 M) | ||||
| Cash And Equivalents | 10.16 M | ||||
| Cash Per Share | 2.07 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.58 X | ||||
| Book Value Per Share | (4.95) X | ||||
| Cash Flow From Operations | (10.07 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (43.68) X | ||||
| Target Price | 2.5 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 1.85 M | ||||
| Total Asset | 3.91 M | ||||
| Retained Earnings | (414.15 M) | ||||
| Working Capital | (3.46 M) | ||||
| Current Asset | 15.34 M | ||||
| Current Liabilities | 3.91 M | ||||
| Net Asset | 3.91 M |
About Yield10 Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Yield10 Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Yield10 Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Yield10 Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Yield10 Bioscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Yield10 Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Yield10 Bioscience will appreciate offsetting losses from the drop in the long position's value.Moving against Yield10 Stock
| 0.83 | IPI | Intrepid Potash | PairCorr |
| 0.79 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.78 | IE | Ivanhoe Electric | PairCorr |
| 0.66 | CTVA | Corteva | PairCorr |
| 0.63 | MHGVY | Mowi ASA ADR | PairCorr |
The ability to find closely correlated positions to Yield10 Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Yield10 Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Yield10 Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Yield10 Bioscience to buy it.
The correlation of Yield10 Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Yield10 Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Yield10 Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Yield10 Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Yield10 Stock
If you are still planning to invest in Yield10 Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Yield10 Bioscience's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |